CellProtect Nordic Pharmaceuticals’ (CPNP) therapy candidate CellProtect has received orphan drug designation from the European Commission (EC) to treat multiple myeloma.
Six new medicines, including the first hormone replacement therapy for a thyroid disorder, have been put forward for approval by the European Medicines Agency's Committee for Medicinal Products for Human Use.